François Martelet, Chief Executive Officer, joined NetScientific Mid 2015.
He brings over 20 years of biopharma experience and a proven track record of shaping and developing businesses to deliver returns. He has broad experience in both large and small companies, deep knowledge of commercialisation and has proven managerial capabilities. In particular he successfully managed large P&L ($1+B) across large country organizations in senior level regional roles with full accountability of multiple product lines in primary care & specialty markets in Europe and Emerging markets.
Previously, François served as senior advisor to the CEO and Interim SVP at Stallergenes SA where he was responsible for international commercial strategies. During this period, sales revenues grew by 20+% and various new products were launched, including Oralair®, into ex-US markets. Before this, he was CEO at Topotarget A/S, a publicly traded European biotech company specialised in oncology therapeutics which he successfully transformed from a research based organisation into a late-stage clinical development company ready for a European exit.
Prior to this, François served as CEO of Avax Technologies Inc., a US biotech company specialised in therapeutic oncology vaccines. He has also held senior level commercial positions at Merck & Co, Inc. (VP & Global Franchise Head-Oncology), Novartis Pharma (SVP & Head of Central & Eastern Europe, Middle East and Africa), Schering-Plough and Eli Lilly.
François gained a Doctorate in Medicine and a Master’s Degree in Business from Dijon University, and holds a Degree in Legal Medicine from R. Descartes University School of Medicine, Paris. He is also a graduate of the Advanced General Management Program at INSEAD and attended senior executive courses at Harvard Business School.
François Martelet’s awards include the Pasteur Institute medal (1989) Knight of the French National Order Merit (2011) and the Knight of the Legion d’Honneur (2017) which is the highest decoration in France.